Chinese biotech MindRank secures $52m to advance AI-designed oral GLP-1RA - Pharmaceutical Technology

The funds will support the progression of MindRank’s pipeline, which is heavily dominated by obesity indications. The funds will support the progression of MindRank’s pipeline, which is heavily dominated by obesity indications. China represents a major market opportunity for weight loss therapies, both for injectables and next-generation pills. Credit: Boxyray/Shutterstock.com. MindRank has raised $52m to advance its pipeline of candidates discovered and designed by artificial intelligence (AI), including a lead glucagon-like peptide-1 receptor agonist (GLP-1RA) currently in a Phase III trial in China. MindRank, which is based in China’s Zhejiang province capital Hangzhou, has built a Molecule Arts Platform (MAP)…

Source: Pharmaceutical Technology